CClinicalTrials.gg
Status unknownNCT05783778Updated Mar 24, 2023

Evaluation of the Role of Latent Toxoplasmosis in Female Patients With Active Acne Vulgaris

An interventional study of Free testosterone levels and toxoplasma igG in Acne Vulgaris and Toxoplasmosis, sponsored by Sohag University. Status unknown. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-24.

Sponsored by Sohag University · Not applicable, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

Acne vulgaris is one if the most common chronic inflammatory skin disorders.Acne is characterized by forming of inflammatory and non inflammatory lesions mainly on the Face,neck,arms, upper trunk and back

Read the detailed description

One of the hidden hormonal imbalance is Toxoplasma infection.Toxoplasmosis is a zoonotic infection the definite host is feline whereas human and other warm blooded animals are intermediate host . Endocrine alterations occuring during toxoplasmosis can be a hidden cause of acne vulgaris

02

Conditions studied

  • Acne Vulgaris
  • Toxoplasmosis
03

In context

Toxoplasmosis

36 studies on the registry are indexed under Toxoplasmosis; 9 are open to participants now.

This study's planned enrollment of 200 is above the median of 105 across 20 interventional studies indexed under Toxoplasmosis.

Browse Toxoplasmosis studies →

Lead sponsor

Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Female patients with active acne vulgaris

Exclusion criteria

Exclusion Criteria:

  • Patients with history of hormonal treatment Patients received anti toxoplasma therapy Patients with dermatological diseases caused by hormonal disturbances Pregnant and lactating patients
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Toxoplasmosis seropositive female patients with active acne vulgaris

    Diagnostic Test: Free testosterone levels and toxoplasma igG

  • Experimental
    Toxoplasmosis seronegative in female patients with active acne vulgaris

    Diagnostic Test: Free testosterone levels and toxoplasma igG

Interventions

  • Diagnostic testFree testosterone levels and toxoplasma igG

    Free testosterone levels and toxoplasma igG in serum by ELISA

06

What researchers measure

Primary outcomes

  1. Measuring Toxoplasma igG and free testosterone in acne vulgaris patients and controls

    Detect if the toxoplasma latent infection can be associated with disease severity and hormonal disturbances in acne vulgaris female patients

    Time frame: One month

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05783778
Lead sponsor
Sohag University
Responsible party
Zineb Gamee Aly Ahmed (Zienab Gamea Ali Ahmed, Sohag University) — Principal investigator
First posted
Mar 24, 2023
Start date
Jun 1, 2023 (estimated)
Primary completion
Jun 1, 2024 (estimated)
Completion
Dec 1, 2024 (estimated)
Last update
Mar 24, 2023

Study contacts

Wafaa Mohamed Abdel Mageed
Contact
Wafaaderm78@yahoo.com
01008813349
Rasha Ismail Mohamed
Contact
r.alkady21@gmail.com
01006592879

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion